REPORT: Did Recent Court Rulings Force the FDA to Delay Approving Pfizer’s COVID Shots for Infants?

The U.S. Food and Drug Administration (FDA) announced yesterday that it was delaying the approval of Pfizer’s COVID-19 vaccines for young children between the ages of 6 months and 4 years old.

You have to wonder: what has changed? Was anything good and positive from the vaccines actually proved?

In short: it’s all just “dust in the wind” as it used to be until this day also.

Join The True Defender Telegram Chanel Here:

“Pfizer has worked hard to hide the clinical data from their trials from the public, but recent court rulings have not exactly gone their way. The FDA had originally asked the court to delay releasing their clinical data for 75 years, but then agreed to provide 500 pages per month,” reports have stated.

And Aaron Siri eported that Pfizer was joining the FDA in the case.

“As explained in prior posts, in a lawsuit seeking all of the documents the FDA relied upon to license Pfizer’s COVID-19 vaccine, a federal judge shot down the FDA’s requested rate of 500 pages per month and instead ordered the FDA to produce at the rate of 55,000 pages per month starting on March 1.

Since the government has trillions of dollars of our money, it is putting it to good use by fighting to assure that the public has the least amount of transparency possible. To that end, it has now asked the Court to make the public wait until May for it to start producing 55,000 pages per month and, even then, claims it may not be able to meet this rate.

The FDA’s excuse? As explained in the brief opposing the FDA’s request, the FDA’s defense effectively amounts to claiming that the 11 document reviewers it has already assigned and the 17 additional reviewers being onboarded are only capable of reading at the speed of preschoolers.”

Last week, the judge in this case, U.S. District Judge Mark Pittman, denied Pfizer’s request (for now) to join the case.

The next day, Pfizer redlined changes in their 4th quarter earnings release from 2021.

So, Zero Hedge replied with the following posting.

“Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.

Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.

As Rubicon Capital’s Kelly Brown notes on Twitter, the changes center around disclosures of unfavorable safety data.

For example, in Q4 they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”


Zero HedgeHealth Impact News

Leave a Reply

Your email address will not be published.